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Abstract

Author Manuscript

Neonatal quinpirole (NQ) treatment to rats increases dopamine D2 receptor sensitivity persistent
throughout the animal’s lifetime. In Experiment 1, we analyzed the role of α7 and α4β2 nicotinic
receptors (nAChRs) in nicotine behavioral sensitization and on the brain-derived neurotrophic
factor (BDNF) response to nicotine in NQ- and neonatally saline (NS)-treated rats. In Experiment
2, we analyzed changes in α7 and α4β2 nAChR density in the nucleus accumbens (NAcc) and
dorsal striatum in NQ and NS animals sensitized to nicotine. Male and female Sprague-Dawley
rats were neonatally treated with quinpirole (1 mg/kg) or saline from postnatal days (P)1–21.
Animals were given ip injections of either saline or nicotine (0.5 mg/kg free base) every second
day from P33 to P49 and tested on behavioral sensitization. Before each injection, animals were ip
administered the α7 nAChR antagonist methyllycaconitine (MLA; 2 or 4 mg/kg) or the α4β2
nAChR antagonist dihydro beta erythroidine (DhβE; 1 or 3 mg/kg).

Author Manuscript

Results revealed NQ enhanced nicotine sensitization that was blocked by DhβE. MLA blocked the
enhanced nicotine sensitization in NQ animals, but did not block nicotine sensitization. NQ
enhanced the NAcc BDNF response to nicotine which was blocked by both antagonists. In
Experiment 2, NQ enhanced nicotine sensitization and enhanced α4β2, but not 7, nAChR
upregulation in the NAcc. These results suggest a relationship between accumbal BDNF and α4β2
nAChRs and their role in the behavioral response to nicotine in the NQ model which has relevance
to schizophrenia, a behavioral disorder with high rates of tobacco smoking.

*

Corresponding author: brown1@etsu.edu (R.W. Brown).

Peterson et al.

Page 2

Author Manuscript

Keywords
Dopamine D2 receptor; Nicotine sensitization; Brain-derived neurotrophic factor (BDNF); α7
nicotinic receptor; α4β2 nicotinic receptor; Adolescence

1. Introduction
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Individuals diagnosed with schizophrenia smoke tobacco at a much higher rate than the
general population, and the prevalence rate of smoking among individuals diagnosed with
schizophrenia is as much as 88% [1,2]. In addition, individuals diagnosed with
schizophrenia smoke tobacco in a manner different than that of the general population, as
their nicotine intake appears to be higher compared to the normal population. A study by
Weinberger et al. [3] demonstrated that individuals diagnosed with schizophrenia have
higher levels of plasma nicotine and plasma cotinine (a metabolite of nicotine) compared to
control smokers, even when controlling for the amount smoked per day. Consistent with
these findings, Williams et al. [4] showed that 3-hydroxycotinine, a metabolite of cotinine,
was not altered among schizophrenia patients who smoke, suggesting that the increased
plasma nicotine levels are due to increased nicotine intake rather than alterations in
metabolism.

Author Manuscript

Kostrzewa et al. [5] were the first to report that animals treated neonatally with quinpirole, a
dopamine D2/D3 receptor agonist, administered from postnatal days (P) 1–11, 1–21, or 21–
35 produces an increase in sensitivity of the D2 receptor, and this change is independent of a
change in D2 receptor number. Increases of dopamine D2 sensitivity is a hallmark
characteristic in schizophrenia, and these findings are consistent with past work that has
suggested that although there are abnormalities in other neurotransmitter systems in
schizophrenic patients, all of these abnormalities may be the result of dopamine D2
supersensitivity [6,7]. In a series of studies, we have shown that increases in dopamine D2
sensitivity produced by neonatal quinpirole has several consistencies with schizophrenia
and, in fact, we have yet to find a data point that is inconsistent with the disorder [for a
review,see 8]. While there are other neurotransmitter alterations that are present in
schizophrenia that have yet to be investigated e.g., NMDA receptor hypofunction [for a
review,see 9], findings from the neonatal quinpirole model have attained all three types of
validity: face validity in cognitive impairment and PPI deficits [10,11]; construct validity in
significant decreases of neurotrophic factors [12] and decreases of RGS9 expression [13],
and predictive validity, with findings that olanzapine (atypical antipsychotic) treatment
alleviated cognitive impairment and decreases of neurotrophic factor protein [10].

Author Manuscript

Behavioral sensitization is defined as an augmented motor response that occurs with
repeated and/or intermittent exposure to a drug. Sensitization to drugs of abuse has been
described as a progressive and prolonged increase in the locomotor activating effects, such
as horizontal movement and stereotypy following repeated administration [14]. Based on the
behavioral and cellular changes that are induced from psychostimulant exposure,
sensitization is generally accepted as an effective model for the acquisition of addiction in
humans [15]. Although many neural substrates appear to contribute to psychostimulant-
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induced sensitization, the mesolimbic dopamine system plays a critical role [16,17]. We
have shown that neonatal quinpirole enhances nicotine behavioral sensitization in both
adolescent [18] and adult male and female rats [19]. In addition, it enhances the response of
brain-derived neurotrophic factor (BDNF) in the nucleus accumbens [20], a brain area
known to play a critical role in both behavioral sensitization and the rewarding aspects of
drugs, including nicotine [21]. BDNF is involved in synaptic differentiation and
maintenance, and plays a critical role in addiction [22].

Author Manuscript

The present study was designed to analyze several different aspects of nicotine behavioral
sensitization in male and female rats treated neonatally with quinpirole. In both experiments,
we targeted adolescence because this is a critical developmental period when smoking
behavior often begins, especially in cases of substance abuse comorbidity with behavioral
disorders [23]. In Experiment 1, rats neonatally treated with quinpirole were sensitized to
nicotine in adolescence, however, on each day of behavioral testing, we evaluated effects of
either 2 mg/kg or 4 mg/kg of methyllycaconitine (MLA), an α7 nicotinic receptor antagonist
(nAChR) or 1 mg/kg or 3 mg/kg of di-hydro β-erythroidine (DhβE), an α4β2 nAChR
antagonist. These nAChRs were chosen because they have been shown to be important in the
behavioral effects of nicotine [24] in rodents, but there have not been any studies to analyze
the roles of these two nAChRs in nicotine behavioral sensitization in adolescence. In
addition, brain tissue was analyzed for BDNF. In a second experiment, animals were again
neonatally treated with quinpirole, sensitized to nicotine, and brain tissue analyzed for α7
and α4β2 nAChR binding in the dorsal striatum and nucleus accumbens to characterize the
changes in nAChRs relative to behavioral sensitization to nicotine in this model.

2. Methods
Author Manuscript

Subjects

Author Manuscript

A total of 177 offspring from 19 pregnant female Sprague-Dawley rats ordered from Harlan,
Inc (Indianapolis, IN) were used as subjects. The day of birth was recorded as postnatal day
(P)0. All animals were weaned from the female dam at P21, socially housed 3–4 per cage,
and behaviorally tested as adolescents (P30–P49). Adolescence in the rat is based on both
neurobiological changes as well as behaviors that have been associated with adolescence.
More specifically, several studies have characterized adolescence based on neurobiological
changes beginning on P30 and ultimately ending around P60 based on behavioral and
neurobiological changes during this period [25]. One male and one female were used per
litter per drug condition to control for within litter variance. The animals were housed in a
climate-controlled vivarium with food and water available ad libitum with a 12 h on/off
light/dark cycle. All procedures were approved by the University Committee on Animal
Care (UCAC) at East Tennessee State University and the vivarium is fully accredited by the
Association for the Assessment and Accreditation of Laboratory Animal Care (AAALAC).
Animals were given a single daily intraperitoneal (ip) injection of either quinpirole (1
mg/kg) or saline from P1 to 21. All animals were administered 1 mg/kg quinpirole based on
body weight and were placed back into the home cage immediately after injections.
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All animals were tested in a locomotor testing arena painted flat black and measured 91 cm
on each side. Horizontal activity was measured by ANY-Maze software (Stoelting, Wood
Dale, IL), which superimposes a digital grid of lines on to the image of the locomotor arena.
The dependent measure of behavioral sensitization was the total distance traveled in meters
(m).
Experiments 1 and 2. Behavioral Sensitization Procedure

Author Manuscript
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All animals were habituated to the locomotor testing area for three consecutive days from
P30–32. On each of these days, animals were administered ip injection of saline and
behaviorally tested 10 min after the injection, and activity counts were recorded using Any
Maze software. In Experiment 1, beginning the day following habituation on P33, animals
were given an initial ip injection of either an α4β2 nAChR antagonist (dihydro-betaerythroidine 1 mg/kg or 3 mg/kg aka DhβE), an α7 nAChR antagonist (Methyllycaconitine:
2 mg/kg or 4 mg/kg aka MLA) or saline before being placed back into the home cage for 10
min to allow for distribution of the drug. After 10 min, nicotine tartarate (0.5 mg/kg free
base) or saline was ip administered and animals were placed back into the home cage for
another 10 min to allow for drug distribution. Immediately following this 10 min period,
animals were placed in the locomotor arena, and behavior was recorded for 10 min on each
trial and distance (m) was measured. In Experiment 2, the nAChR antagonists were not
administered, and animals were only given nicotine (0.5 mg/kg free base). In both
experiments, testing was performed every other day for 17 days in all groups resulting in a
total of nine days of testing in between the ages of P33 to 49. In both experiments, brain
tissue was harvested on P50. In Experiment 1, tissue was analyzed for BDNF, and in
Experiment 2, tissue was analyzed for nAChR binding using the autoradiographic technique.
Experiment 1. BDNF ELISA Procedure

Author Manuscript

Twenty-four hours after the last testing session, animals were rapidly decapitated and brain
tissue removed. The brain tissue was immediately frozen in cold (−20 °C) isopentane and
stored in a −80 °C freezer. The nucleus accumbens and dorsal striatum were dissected from
each individual brain and then again stored at −80 °C, and this tissue was used for BDNF
analysis. For the ELISA, we followed procedures previously published [20]. In brief, 250 μl
of RIPA cell lysis buffer (150 mM NaCL, 50 mM Tris-HCl, 1.0% NP-40, 0.5% Sodium
deoxycholate and 0.1% SDS) plus protease and phosphatase inhibitors (P5726, P8340,
P0044, Sigma-Aldrich, St. Louis, MO) was added to each tissue sample and homogenized
using a Fisher Scientific sonic dismembrator 500 (Fisher Scientific, Inc, Atlanta, GA).
Homogenates were then centrifuged at 14,000g for 20 min at 4 °C, and the resulting
supernatants were refrigerated until the following day when the ELISA was performed. All
samples were analyzed according to instructions provided using a BDNF ELISA kit
purchased from Promega Scientific (Madison, WI). For the BDNF assay, anti-BDNF
monoclonal antibody (mAb) was added to a carbonate coating buffer (pH 9.7, per
specifications included with the Promega protocol for BDNF), and 100 μl of the coating
buffer was added to each well of a 96-well polystyrene ELISA plate (MaxiSorb, Nalge Nunc
International, Rochester, NY) and incubated overnight at 4 °C. All wells were washed using
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wash buffer and incubated at room temperature for 1 h. The BDNF standard curve was
prepared using the BDNF standard supplied by the manufacturer (1 μg/ml). The standard
was diluted in Block & Sample 1× buffer to achieve a concentration range of 0–500 pg/ml.
Tissue samples were further diluted 1:2 before being assayed. The standards and samples
were incubated with shaking at room temperature for 2 h. Anti-human BDNF pAB was then
added to each well plate, incubated at room temperature (2 h), which was followed by
incubation (1 h) with anti-IgY horseradish peroxidase (HRP) conjugate. Visualization was
achieved by adding TMB one solution to each well followed by an incubation period of 10
min at room temperature, and this reaction was stopped by adding 1N hydrochloric acid to
each well and plates were read within 30 min of stopping reaction. Optical density was
measured using a Bio-Tek ELx 800 microplate reader (Winooski, VT).
Experiment 2, autoradiography of nAChRs

Author Manuscript
Author Manuscript

After brains were removed, the brain tissue was frozen in isopentane that was chilled in dry
ice. Brains were sliced using a Leica CM 3050S cryostat (Nussloch, Germany) to make a
series of 20-μm thick sections, which were mounted onto gelatin coated slides. Adjacent sets
of sections were prepared to analyze α7 and α4β2 nAChR binding. Alpha α7 nAChRs were
measured using α-[125I]-Bungarotoxin autoradiography, as previously described [26,27]. A
ligand concentration of 2.5 nmol [125I] Tyr54-α-BTX (Perkin-Elmer Life Sciences, Inc.,
Boston, MA; specific activity = 102.9Ci/mmol) was used for section incubations. For α4β2
nAChRs, total binding density was assessed using [125I]-Epibatidine at a concentration of
500 pM (Perkin-Elmer Life Sciences, Inc., Boston, MA; specific activity 2200Ci/mmol), and
nonspecific binding was assessed using both [125I]-Epibatidine at a concentration of 500 pM
and cytisine at a concentration of 100 nM. Amersham ECL high performance
chemiluminescence film (GE Healthcare, Pollards Wood, UK) was used to visualize the
areas of ligand binding. Radioactive rat brain tissue standards were included with each film
X-ray cassette in order to determine the response of the film to the increasing amounts of
radioactivity. Exposure time was optimized for each ligand: 7 days for [125I]-BTX, and 30
days for [125I]-Epibatidine. All films were processed using Kodak D-19 developer.
Quantification of nAChR binding
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Digital images were captured using a light box and Retiga 2000R CCD camera (QImaging,
Surrey, BC, Canada). Autoradiograms were quantified with a computer-based image
analysis system (MCID Elite software 7.0, Imaging Research, St. Catherine, Ontario,
Canada) using calibrated standards of reference (American Radiolabeled Chemicals, St.
Louis, MO). Calibration curves against radioligand concentration were constructed using
[14C] standards of known radioactivity. The reported binding density is the average of
radioactivity, determined from the standard, measured across hundreds of pixels located
within a defined area of the film (representing the either dorsal striatum or NAcc).
Research Design and Rationale for Dosing
In Experiment 1, there were three factors in the design: sex (male, female), neonatal drug
treatment (quinpirole, saline), and adolescent drug treatment (saline + saline, saline+
nicotine, MLA (two doses) +NIC, DhβE (two doses) +NIC,). Note that there was not a
group included in which only the nAChR antagonist was given followed by saline. The
Behav Brain Res. Author manuscript; available in PMC 2018 May 15.
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rationale for not including these groups was that the focus of the study was to analyze the
roles of α7 and α4β2 nAChR in behavioral sensitization and BDNF response to nicotine in
Experiment 1, not the antagonist administered by itself, which would likely produce a
completely different response not related to the present focus of the study. The dependent
measure for behavioral sensitization was a mean of the distance travelled on day 1
subtracted from the distance travelled on day 9, which was the last day of behavioral
sensitization testing. The rationale for this dependent measure was to avoid a four factor
design which makes the interpretation of higher-order interactions complex.

Author Manuscript

A three-way ANOVA was used as the primary statistic and all post hoc comparisons were
performed with Newman-Keuls post hoc tests (p = 0.05). The doses chosen for these
experiment were based on past work from our laboratory which has shown that a 0.5 mg/kg
dose of NIC produces robust behavioral sensitization in both neonatal saline and quinpirole
treated animals, with neonatal quinpirole resulting in enhanced behavioral sensitization to
nicotine in adolescence [20]. Both MLA and Dhβe were chosen as our nAChR antagonists
based on several studies showing that these compounds have been used to effectively test the
roles of α7 and α4β2 nAchRs in both the behavioral [28] and neurochemical effects of
nicotine [29,30]. For Experiment 2, there were no antagonists administered, and animals
were given the same neonatal drug treatment as Experiment 1, but adolescent drug treatment
was either saline or nicotine (0.5 mg/kg free base) every second day from P33–49, identical
to Experiment 1. In Experiment 2, density of α7 and α4β2 nAChR binding was the
dependent measure, and both the dorsal striatum and nucleus accumbens were analyzed.
Group Coding

Author Manuscript

Group codes for neonatal drug treatment are NQ = neonatal quinpirole and NS = neonatal
saline. For adolescent drug treatment all animals were given two injections, the first of
which was either the antagonist or saline, and the second of which was nicotine or saline.
Group codes for adolescent drug treatment are presented with the first drug followed by the
second drug in the order they were injected, and include: SS = saline/saline, SN = saline/
nicotine, 1 mg/kg DN = 1 mg/kg DhβE/nicotine, 3 mg/kg DN = 3 mg/kg DhβE/nicotine, 2
mg/kg MN = 2 mg/kg MLA/nicotine, and 4 mg/kg MN = 4 mg/kg MLA/nicotine (See Figs.
1–5). Note that in Experiment 2, all groups were given a saline injection followed by either
saline or nicotine to mimic the two injection protocol of Experiment 1, thus, in Experiment 2
there are only SS and SN groups represented.

Author Manuscript

Several statistical analyses were performed. First, an omnibus three-way ANOVA was
performed on behavioral sensitization, BDNF levels, and nAChR binding, and simple effects
were used to analyze any significant interactions. Further, in Experiment 1 only, we
performed a specific comparison (two-way ANOVA) on groups that received either MLA or
DhβE. The rationale for this ANOVA was to compare the function of the α7 and α4β2
nAChR in both behavior and accumbal BDNF in different neonatal drug treatment
conditions. Finally, an independent t-test was performed to compare NQ and NS rats that
received nicotine with no antagonist. The rationale for this comparison was to analyze
whether NQ treatment changed the response to nicotine on all dependent measures
compared to control animals that also received nicotine.
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3. Results
Experiment 1, Behavioral Sensitization
An initial, two-way ANOVA (sex, neonatal drug treatment) was used to analyze the overall
mean of the three habituation trials, and revealed a significant main effect of sex, F(1,55) =
24.4, p < 0.001. Females demonstrated an overall increase in activity compared to males,
however, this baseline level of activity was not affected by neonatal drug treatment (data not
shown). Fig. 1 represents distance travelled as a function of group. A three-way ANOVA
revealed significant main effects of sex, F(1,176) = 16.8, p < 0.001, neonatal drug treatment,
F(1,176) = 17.6, p < 0.001, adolescent drug treatment F(5,176) = 32.72, and a significant
interaction of neonatal drug treatment × adolescent drug treatment, F(5,176) = 4.71, p <
0.001.
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Author Manuscript

The neonatal drug treatment × adolescent treatment interaction was analyzed through simple
effects analyses. Specifically, two separate one-way ANOVAs (adolescent drug treatment)
were performed for neonatal drug treatment of saline (NS) and quinpirole (NQ). For NStreated animals, there was a significant main effect of adolescent drug treatment, F(5,88) =
9.07, p < 0.011. Post hoc analyses revealed that NS animals receiving saline followed by
nicotine (SN) demonstrated equivalent levels of activity to both MLA-treated groups and the
1 mg/kg DhβE group, which were significantly greater than all other groups receiving NS.
For NQ-treated animals, there was also a significant main effect of adolescent drug
treatment, F(5,87) = 23.34, p < 0.001. NQ animals receiving saline followed by nicotine
(SN) demonstrated significantly higher levels of activity than all other groups. In addition,
the NQ groups receiving MLA demonstrated significantly higher levels of activity than both
NQ groups receiving DhβE and saline controls. Saline controls and NQ rats that received
DhβE, regardless of dose, did not significantly differ. Finally, an independent groups t-test
revealed that the NQ group receiving SN treatment in adolescence demonstrated
significantly higher levels of activity than the NS group also receiving SN treatment, t(29) =
4.37, p < 0.001. This analysis revealed that indeed NQ enhanced behavioral sensitization to
nicotine compared to NS animals. To summarize, NQ produced more robust sensitization to
nicotine than controls given nicotine, and DhβE was more effective at blocking nicotine
sensitization than MLA, however, MLA was less effective in NQ treated groups as compared
to NS groups.

Author Manuscript

A final analysis compared only the groups that received an nAChR antagonist. The rationale
for this analysis was to investigate whether MLA or DhβE resulted in group differences in
behavioral sensitization based on neonatal drug treatment. A two-way ANOVA including
only NQ and NS groups that received MLA or DhβE revealed significant effects of neonatal
drug treatment, F(1,118) = 4.39, p < 0.03, adolescent drug treatment, F(3,118) = 13.82, p <
0.001, and a significant interaction of neonatal drug treatment × adolescent drug treatment,
F(3,118) = 3.88, p < 0.011. Newman-Keuls post hoc comparisons revealed Group NQ
animals which received MLA demonstrated significantly greater activity than the NS group
that received MLA, regardless of dose. However, NQ and NS animals which received DhβE
were equivalent, regardless of dose. This result indicates that α7 nAChR antagonism was
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less effective to block nicotine sensitization in NQ compared with NS animals, but this was
not the case with DhβE.
Experiment 1, BDNF assay
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An initial three-way ANOVA revealed no significant main effect or interactions of sex, so
this factor was dropped from subsequent analyses. A two-way ANOVA (neonatal drug
treatment × adolescent drug treatment) revealed significant main effects of neonatal drug
treatment, F(1,118) = 9.44, p < 0.003, adolescent drug treatment, F(5,118) = 33.98, p <
0.001, and a significant neonatal drug treatment × adolescent drug treatment interaction,
F(5,118) = 8.22, p < 0.001. The neonatal drug treatment × adolescent treatment interaction
was analyzed through simple effects analyses. For the NS groups, there was a significant
main effect of adolescent drug treatment, F(5,73) = 12.04 p < 0.001. Newman-Keuls post
hoc analyses demonstrated that the NS group receiving saline followed by nicotine had
significantly higher levels of accumbal BDNF than all other groups. In addition, the NS
group receiving saline demonstrated significantly higher levels of accumbal BDNF than all
other groups that received either nAChR antagonist, and the nAChR antagonist groups did
not significantly differ from each other. For the NQ groups, the simple effects analysis also
revealed a significant main effect of adolescent drug treatment, F(5,56) = 25.91, p< 0.001.
Post hoc analysis demonstrated the NQ group that received saline followed by nicotine was
significantly higher than all other groups, which did not significantly differ from each other.
Finally, an independent groups t-test was utilized to analyze the comparison between SN
groups that received NQ or NS neonatal treatment, and similar to behavioral sensitization
that analysis was statistically significant, t(29) = 4.37, p < 001. NQ enhanced the NAcc
BDNF response to nicotine compared to NS treated group given nicotine.

Author Manuscript

Similar to behavioral sensitization, a final analysis compared only the groups that received
an nAChR antagonist. The rationale for this analysis was to investigate whether MLA or
DhβE resulted in group differences in BDNF based on neonatal drug treatment. A two-way
ANOVA including only NQ and NS groups that received MLA or DhβE revealed only a
significant main effect of adolescent drug treatment, F(3,72) = 6.64, p < 0.001. Overall, the
highest dose of DhβE demonstrated the lowest NAcc BDNF protein compared to all other
groups, which did not significantly differ from each other. Therefore, unlike behavioral
sensitization, the change in BDNF relative to nAChR antagonist treatment did not
significantly differ based on neonatal drug treatment.
Experiment 2, Behavioral Sensitization

Author Manuscript

An initial two-way ANOVA (sex, neonatal drug treatment) of the mean activity during
habituation revealed a significant main effect of sex, (F1,48) = 6.5, p< 0.02. Similar to the
results of Experiment 1, females demonstrated an overall increase in activity as compared to
males (data not shown). The main effect of neonatal drug treatment and the interaction were
not significant.
With respect to behavioral sensitization, the three-way ANOVA (sex × neonatal drug
treatment × adolescent drug treatment) did not reveal a significant main effect or interactions
of sex, so this factor was dropped from subsequent analyses. A two-way ANOVA (neonatal
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drug treatment × adolescent drug treatment) revealed significant main effects of neonatal
drug treatment, F(1,48) = 12.27, p < 0.001, adolescent drug treatment, F(1,48) = 57.05, p<
0.001, and a significant interaction of neonatal drug treatment × adolescent drug treatment,
F(1,48) = 5.18, p< 0.028. Based on the comparison of only four groups and to simplify the
analysis, simple effects were not used and a Newman-Keuls post hoc test was used to reveal
that NQ group receiving SN treatment was significantly greater than all other groups. In
addition, the NQ group receiving SN treatment was significantly greater than saline-treated
groups, which did not significantly differ from each other. Essentially, these results replicate
the effect observed in Experiment 1 and those of Perna & Brown [20] showing that NQ
results in enhanced behavioral sensitization to nicotine.
Experiment 2, Autoradiographic analyses of nAChR density
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Density of receptor binding is represented as nanocuries per milligram of tissue (nCI/mg) for
[125I] alpha-bungarotoxin (α7 nAChRs) and [125I epibatidine (α4β2 nAChRs) in Fig. 4a and
b, respectively. As with other analyses, no significant main effect or interactions were
revealed with sex as a factor, regardless of the ligand analyzed or brain area (although it
should be noted only 3–4 males and females were used in each drug condition). Therefore, a
two-way ANOVA (neonatal drug treatment × adolescent drug treatment) was used for each
α7 and α4β2 nAChRs with a total N of 6–7 per drug condition per brain area. For α7
binding in the NAcc, a two-way ANOVA revealed a significant main effect of adolescent
drug treatment, F(1,25) = 6.64, p < 0.017 and a significant interaction of neonatal drug
treatment × adolescent drug treatment, F(1,25) = 6.80, p < 0.016. Post hoc analyses revealed
that the NS group receiving SN treatment demonstrated a significant increase of α7 nAChR
binding in the NAcc relative to the other three groups, which did not significantly differ
from each other. Therefore, NQ appears to have blocked the increase of α7 binding in the
NAcc. In the dorsal striatum, a two-way ANOVA also revealed a significant interaction of
neonatal drug treatment × adolescent drug treatment, F(1,27) = 4.47, p< 0.045. Post hoc
analyses revealed that both the NS group receiving SN and the NQ group receiving SS were
equivalent, and both demonstrated significantly increased α7 binding compared to NS
receiving SS and NQ receiving SN. Similar to the NAcc, NQ appears to have blocked
increased α7 binding in the dorsal striatum, however, NQ significantly increased α7 binding
in the dorsal striatum in animals given saline, a finding that replicates past work by Tizabi et
al. [31].
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Regarding [125I] epibatidine binding in the NAcc, a two-way ANOVA revealed significant
main effects of neonatal drug treatment, F(1,26) = 17.84, p < 0.001, adolescent drug
treatment, F(1,26) = 71.31, p < 0.001, and a significant interaction of neonatal drug
treatment × adolescent drug treatment, F(1,26) = 9.72, p < 0.001. Post hoc analyses revealed
a robust significant increase of [125I] epibatidine binding in the NQ group receiving SN
compared all other groups. In addition, the NS group receiving SN demonstrated a
significant increase in [125I] epibatidine binding compared to both groups receiving saline,
and the latter two groups did not differ significantly. In the dorsal striatum, there were no
significant main effects or interaction revealed. Interestingly, changes in α4β2 nAChRs
appear to be directed toward the NAcc.
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4. Discussion
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This study revealed several key findings relative to nicotine’s effects on behavioral
sensitization, accumbal BDNF, and changes in α7 and α4β2 nAChRs in the NAcc and
dorsal striatum in the NQ model. Replicating previous work [18,20], both experiments
demonstrated that NQ robustly enhanced behavioral sensitization to nicotine in adolescent
animals. With increased dopamine D2 receptor sensitivity that is present in the NQ model,
the current findings have implications regarding the differential roles of nAChRs and BDNF
in the behavioral response to nicotine under the conditions of increased dopaminergic
signaling. Specifically, it was discovered that the α4β2 receptor appears to play a more
prominent role in the induction of the behavioral sensitization to nicotine than does the α7
nAChR, based on the result that both NQ and NS animals that received either dose of the
α4β2 nAChR antagonist DhβE demonstrated significantly lower activity levels than animals
administered the α7 antagonist MLA or saline. This finding supports past work that has
shown that in general, the α4β2 nAChR has been found to play a more prominent role in the
behavioral sensitization to nicotine [32]. However, no previous work has analyzed the
differential role of these two nAChRs in adolescent nicotine sensitization. Further, Tapper et
al. [33] demonstrated that activation of α4 nAChRs was sufficient for nicotine-induced
reward, tolerance, and sensitization. The findings here extend this previous work toward a
model of dopamine D2 supersensitivity with implications towards schizophrenia.

Author Manuscript

An important discovery is that NQ produced an identical pattern of enhanced BDNF
response to nicotine and α4β2 nAChR upregulation in the NAcc. BDNF has also been
shown to be important in the brain’s reward pathways [see 34 for review], and accumbal
BDNF and its receptor tyrosine kinase B (trkB)interactions in the NAcc have been shown to
play a critical role in behavioral processes directly related to addiction [35–37]. The present
study extends these previous findings, demonstrating that NQ treatment, which increases
sensitivity of the dopamine D2 receptor, enhanced sensitization to nicotine in adolescence as
well as the accumbal BDNF response and α4β2 nAChR binding relative to all other groups.
In NS animals, nicotine produced a significant increase in both BDNF and α4β2 nAChRs
compared to controls. This finding, coupled with the fact that these changes are occuring
during adolescence when tobacco smoking often initiates, underlines the relevance of this
result. Further, there is strong evidence in research on nicotine dependence that supports
genetic associations of the α4 nAChR subunit (CHRNA4) with tyrosine kinase B (TrkB;
NTRK2), which is the receptor to which BDNF binds [38–41]. Therefore, it appears that not
only may there be an existing relationship between α4β2 nAChRs and BDNF, especially in
the NAcc, but this relationship is also observed in NQ-treated rats, a model of dopamine D2
receptor supersensitivity with relevance to schizophrenia.

Author Manuscript

It is important to point out that there was no differential behavioral response to either
nAChR antagonist due to neonatal drug treatment. One issue here may be that the changes
reported in nAChR binding density may not be a good indicator of nAChR activity, or that
changes in nAChR density within the NAcc may not be related to behavioral sensitization.
However, past work has demonstrated that accumbal infusion of nAChR antagonists blocked
increases in dopamine release in the NAcc and accumbal dopamine activity has been shown
to mediate the behavioral effects of nicotine [42,43]. Another potential issue is that these
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nAChR antagonists were administered over an 18-day period, every second day, during
adolescence. How this subchronic treatment of nAChR antagonists affected receptor density
and/or nAChR sensitivity is unknown, which may also play a role in the behavioral results
observed in the present study.

Author Manuscript

Interestingly, the common smoking cessation treatment, varenicline (Trade name: Chantix),
which is a partial agonist at the α4β2 nAChR, has been generally shown to be effective for
smoking cessation in populations diagnosed with psychosis [44], and the more robust
upregulation of α4β2 nAChR density in NQ animals observed in the present study is
consistent with this outcome. Past work has shown that there is a complex interaction
between dopamine D2 receptors and α4β2 nAChRs in the striatum, with α4 nAChRs and
dopamine D2 receptors both co-localized on cholinergic interneurons. Research has shown
that when dopamine levels decrease, it results in disinhibition of these cholinergic
interneurons [45–47]. Likewise, nicotine results in inhibition of these cholinergic
interneurons in the dorsal striatum [48]. If dopamine D2 receptors are increased in their
sensitivity and the dopamine system is activated by nicotine, it may contribute to further
inhibition of these interneurons. For example, findings have shown that application of
nicotine in striatal slices inhibits cholinergic interneurons and conversely, blockade of
nAChRs increases burst firing [48]. In a system with increased sensitivity of dopamine D2
receptors, nicotine may result in possible silencing of cholinergic interneurons with the
combined activation of α4β2 nAChRs through nicotine’s agonist action and increased
sensitivity of dopamine D2 receptors of these interneurons, which may contribute to
increased burst firing. Ultimately, this may result in significant increases of dopamine in
response to nicotine in NQ-treated rats [20]. More research on this mechanism will be a
focus of future work.

Author Manuscript
Author Manuscript

Interestingly, a completely different pattern emerged for the effects of NQ on α7 nAChR
density after nicotine treatment, including NQ resulting in an α7 nAChR downregulation in
the NAcc in response to nicotine. Past work has shown that dopamine D2 and α7 nAChRs
are co-localized on many of the same postsynaptic dendrites and astrocytes in the prefrontal
cortex [49], as well as the same neurons in the ventral tegmental area (VTA) [50]. Of course,
the VTA is located in the midbrain and sends major dopaminergic projections to both the
prefrontal cortex and NAcc, and both pathways have been strongly implicated in addiction.
Garzon and colleagues [50] suggest that antipsychotic drugs, all of which block the
dopamine D2 receptor with some affinity [51], may act in the VTA to facilitate α7 nAChR
burst firing by elimination of D2 receptor inhibition in neurons expressing both receptors.
This may actually work the opposite in the present case, because dopamine D2 receptors are
increased in their sensitivity. That is, we found that NQ rats that received saline resulted in a
significant upregulation of α7 nAChRs in the striatum at P50, supporting past data from
Tizabi and colleagues [31] that found α7 nAChRs are upregulation in the striatum at P30
after NQ treatment (identical to the treatment given in the present study). However, when
nicotine was administered subchronically, α7 nAChRs were found to be down-regulated in
the NAcc. We suspect that this downregulation may be due to colocalization of dopamine D2
receptors and α7 nAChRs, and when nicotine is administered, it acts to inhibit the
supersensitized dopamine D2 autoreceptor [52], increasing activation of the dopamine
system and ultimately resulting in a downregulation, or possibly, densensitization of
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accumbal α7 nAChRs. While this is speculative, it has been established that increases of
dopamine activation, similar to what occurs in schizophrenia, ultimately results in a
downregualtion of α7 nAChRs [53]. However, there are no reports on changes in the α7
nAChR in brain areas mediating drug reward, nor is there any data on the density of nAChRs
in brain reward areas during the adolescent period. Further, the characteristics of nAChRs in
reward areas of the brain in schizophrenic smokers is also unknown.

Author Manuscript

Past work has established a relationship between both α7 and α4β2 nAChRs and BDNF in
different brain regions. For example, it has been shown that BDNF can lead to upregulation
of α7 nAChRs on hippocampal interneurons [54], and chronic mecamylamine, a noncompetitive nAChR antagonist, reduced BDNF in the pre-frontal cortex [55]. Nicotine
directly injected into the hippocampus also resulted in an increased in BDNF mRNA [56],
and chronic, but not acute, nicotine has been shown to increase hippocampal BDNF [57].
Therefore, it was not necessarily surprising that both MLA and DhBE resulted in a
significant decrease of accumbal BDNF, but there were no significant group differences
between the two antagonists used. This suggests that there is a close relationship between
BDNF and nAChRs, and antagonism of either α7 or α4β2 nAChRs is sufficient to produce a
significant decrease of BDNF in brain areas that mediate drug reward.

Author Manuscript
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Antagonism of α7 nAChR with MLA failed to block nicotine sensitization in both NQ and
NS animals, however, it was more effective in NS-treated animals. On the other hand,
antagonism of the α4β2 completely blocked nicotine sensitization in both NQ and NStreated animals, and there were no significant differences between these groups based on
neonatal drug treatment. Importantly, these two nAChRs have not been directly compared in
behavioral sensitization to nicotine when an antagonist was administered each day of
nicotine administration as was done in the present study. Furthermore, there have not been
any studies that have analyzed the relationship between nAChRs and behavioral sensitization
to nicotine exposure in adolescence, so this is the first study to analyze nAChRs during this
critical period in which nicotine addiction often begins [58]. The fact that MLA was less
effective in NQ animals, but NQ animals in Experiment 2 demonstrated downregulation of
α7 nAChRs compared NS-treated rats was somewhat surprising. It may be that the D2
supersensitization that is produced by neonatal quinpirole treatment not only produces
downregulation of α7 naChRs, but may also reduce their sensitivity to antagonism. Our
hypothesis is that the upregulation of dorsal striatum α7 nAChRs produced by NQ treatment
may be important in the initial response to nicotine in NQ rats, but as nicotine is continually
administered, α4β2 nAChRs play a more prominent role in the behavioral response to
nicotine. Supporting this idea, past work has shown that chronic nicotine selectively
upregulates α4β2 nAChRs in the nigrostriatal pathway as well as enhanced MLA-resistant
nicotinic currents in substantia nigra GABA neurons [59] in both slice and intact mice. This
would support the hypothesis that as nicotine is sub-chronically administered, the α4β2
nAChR is critical in nicotine sensitization in both NQ and NS-treated rats.
In conclusion, the present study characterizes the relationship of behavioral sensitization to
nicotine and BDNF and two prominent nAChRs in a model of dopamine D2 receptor
supersensitivity during adolescence, a critical period of development for not only the
dopamine system [60] but also for the initiation of smoking behavior. Future work is aimed
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at more fully analyzing the neural plasticity response to nicotine in adolescence, sex
differences that may exist, and mechanisms downstream from BDNF that may lead to the
discovery of pharmacological targets for smoking cessation in schizophrenia and psychosis.
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The difference in distance traveled is presented as a function of neonatal drug treatment (xaxis) and adolescent drug treatment (legend) for behavioral sensitization in Experiment 1.
Group NQ administered SN demonstrated significantly higher distance traveled during
behavioral sensitization than all other groups (indicated by **, p < 0.05). All groups given
nicotine with the exception of the NS groups administered 3 mg/kg DN and both NQ DN
groups demonstrated significantly greater distance traveled during behavioral sensitization
than controls (Group NS administered SS; indicated by *, p < 0.05).
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NAcc BDNF (pg/mg) protein is presented as a function neonatal drug treatment (x-axis) and
adolescent drug treatment (legend). Group NQ administered SN demonstrated significantly
higher BDNF protein levels in the NAcc than all other groups (indicated by **, p < 0.05).
Group NS administered SN demonstrated significantly higher BDNF protein levels in the
NAcc than controls (Group NS and NQ administered SS) and all groups given an antagonist
(indicated by *, p < 0.05). All antagonist groups demonstrated significantly lower NAcc
BDNF protein levels than controls (indicated by #, p < 0.05).
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The difference in distance traveled is presented as a function of neonatal drug treatment (xaxis) and adolescent drug treatment (legend) for behavioral sensitization in Experiment 2.
Group NQ administered SN demonstrated significantly higher distance traveled than all
other groups (indicated by **, p < 0.05). NS Group administered SN demonstrated
significantly higher distance traveled than controls (Group NS and Group NQ administered
SS; indicated by *, p < 0.05).
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The density of binding (nCi/mg) is presented as a function of neonatal drug treatment (xaxis) and adolescent drug treatment (legend) α7 nAChR binding in the NAcc (A) and dorsal
striatum (B). In the NAcc, NS administered SN demonstrated significantly higher α7
nAChR binding than all other groups (indicated by *, p < 0.05). In the dorsal striatum,
Group NS and Group NQ administered SS were equivalent and demonstrated significantly
higher BDNF protein levels than the other groups (indicated by *, p < 0.05).
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The density of binding (nCi/mg) is presented as a function of neonatal drug treatment (xaxis) and adolescent drug treatment (legend) α4β2 nAChR binding in the NAcc (A) and
dorsal striatum (B). In the NAcc, NQ administered SN demonstrated significantly higher
α4β2 nAChR binding than all other groups (indicated by **, p < 0.05). Group NS
administered SN demonstrated significantly higher α4β2 nAChR binding than controls
administered SS (indicated by *, p < 0.05). In the dorsal striatum, there were no significant
differences between groups.
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